Clinical trial · Observational
Serum IGF-1 and IGF-1Ec in Malignancy Assessment
Evaluation of Serum IGF-1 and IGF-1Ec (E-peptide/MGF) Levels and Their Association With Tumor Burden in Patients With Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This cross-sectional study investigates the relationship between serum IGF-1 and IGF-1Ec (E-peptide/MGF) levels and tumor burden in patients with solid tumors. By analyzing serum samples using ELISA and correlating them with clinical data such as tumor stage, size, metastasis, and lymph node involvement, the study aims to explore whether these biomarkers-particularly IGF-1Ec and the IGF-1Ec/IGF-1 ratio-can reflect tumor progression and serve as potential prognostic indicators.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| IGF1R | — | UNRESOLVED | — |
| Solid Cancers | Malignant Solid Neoplasm | ALIAS | 0.90 |
| Solid Tumor Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- The study group will consist of at least 60 adult patients (aged 18 and older) with histologically confirmed solid tumors who are clinically stable and have not yet started or are in the early phase of standard chemotherapy. Participants will be recruited from the outpatient and inpatient oncology units at Çanakkale Onsekiz Mart University. Individuals with hematological malignancies, organ failure, or conditions/medications affecting IGF-1 levels will be excluded.
Primary outcomes (1)
- measure
- IGF-1 and IGF-1Ec levels
- timeFrame
- From enrollment to 6 month
- description
- Blood values
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed diagnosis of a solid tumor * Clinically stable condition, prior to chemotherapy or during standard follow-up * Ability to provide informed consent Exclusion Criteria: * Hematological malignancies (e.g., leukemia, lymphoma) * Acute or chronic liver or kidney failure * Current use (within 1 month) of corticosteroids, growth hormone, or medications affecting IGF-1 levels * Pregnancy or lactation * Coagulopathy or severe anemia preventing safe venipuncture
References
Publications (0)
Data not yet available